Chinese Scientists Encapsulate Mitochondria to Combat Parkinson’s Disease

On March 20, Chinese scientists announced the creation of a mitochondrial capsule designed to safely and effectively transport these tiny energy-producing organelles into cells and tissues. This innovation opens up promising new pathways for treating diseases linked to mitochondrial dysfunction, such as Parkinson’s disease.

The breakthrough was achieved by researchers from the Guangzhou Institutes of Biomedicine and Health, part of the Chinese Academy of Sciences, in collaboration with Guangzhou Medical University. The team encases mitochondria within vesicles derived from red blood cell membranes, as detailed in a recent publication in the journal Cell. Animal studies demonstrated a marked improvement in transplantation success using this method.

Mitochondria are recognized as the energy centers within human cells. Approximately one in every 5,000 individuals worldwide suffers from inherited mitochondrial genetic disorders. Mitochondrial malfunction is also a significant factor in neurodegenerative and metabolic diseases, including Parkinson’s, Alzheimer’s disease, and diabetes.

Until now, repairing mitochondrial issues at their root has been a challenge. One potential treatment involved transplanting healthy mitochondria into affected cells or tissues, but success rates were typically below 5 percent. Using mitochondrial capsules, however, increased this success rate to about 80 percent, according to the research team. Once inside cells, these capsules actively integrate with the cell’s existing energy network, continuing to provide functional support.

In experiments with mice suffering from Parkinson’s disease, the mitochondrial capsules delivered to the affected brain regions effectively prevented further neuron loss, restored normal mitochondrial function, and significantly improved motor skills, nearly restoring them to normal levels, the study reported.

In another mouse model with mitochondrial genetic disease, the capsules notably extended lifespan and prevented multi-organ deterioration, the researchers found.

The key to future clinical application will be large-scale production and rigorous quality control of mitochondrial capsules, said Zhu Hongming, a doctoral supervisor at Tongji University School of Medicine. He added that if clinical trials succeed, this technology could not only treat neurodegenerative and metabolic disorders but also potentially address issues like heart failure and organ aging.